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Background: Chlamydia trachomatis is an obligate intracellular human pathogen causing ocular and urogenital
infections that are a significant clinical and public health concern. This bacterium uses a type III secretion (T3S)
system to manipulate host cells, through the delivery of effector proteins into their cytosol, membranes, and
nucleus. In this work, we aimed to find previously unidentified C. trachomatis T3S substrates.
Results: We first analyzed the genome of C. trachomatis L2/434 strain for genes encoding mostly uncharacterized
proteins that did not appear to possess a signal of the general secretory pathway and which had not been
previously experimentally shown to be T3S substrates. We selected several genes with these characteristics and
analyzed T3S of the encoding proteins using Yersinia enterocolitica as a heterologous system. We identified 23
C. trachomatis proteins whose first 20 amino acids were sufficient to drive T3S of the mature form of β-lactamase
TEM-1 by Y. enterocolitica. We found that 10 of these 23 proteins were also type III secreted in their full-length
versions by Y. enterocolitica, providing additional support that they are T3S substrates. Seven of these 10 likely T3S
substrates of C. trachomatis were delivered by Y. enterocolitica into host cells, further suggesting that they could be
effectors. Finally, real-time quantitative PCR analysis of expression of genes encoding the 10 likely T3S substrates of
C. trachomatis showed that 9 of them were clearly expressed during infection of host cells.
Conclusions: Using Y. enterocolitica as a heterologous system, we identified 10 likely T3S substrates of C.
trachomatis (CT053, CT105, CT142, CT143, CT144, CT161, CT338, CT429, CT656, and CT849) and could detect
translocation into host cells of CT053, CT105, CT142, CT143, CT161, CT338, and CT429. Therefore, we revealed
several C. trachomatis proteins that could be effectors subverting host cell processes.
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Chlamydiae are a large group of obligate intracellular
bacteria that includes human pathogens (e.g. Chlamydia
trachomatis or C. pneumoniae), animal pathogens (e.g.
C. abortus, C. caviae, C. felis, or C. muridarum), or sym-
bionts of free-living amoebae. Among Chlamydiae, C.* Correspondence: ljmota@fct.unl.pt
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unless otherwise stated.trachomatis is a particular clinical and public health con-
cern, being the leading cause of infectious blindness in de-
veloping countries [1] and the most prevalent sexually
transmitted bacteria worldwide [2].
Like all Chlamydiae, C. trachomatis undergoes a deve-
lopmental cycle involving the inter-conversion between
two morphologically distinct forms: a non-replicative
infectious form, the elementary body (EB), and a replica-
tive non-infectious form, the reticulate body (RB) [3].
Throughout its developmental cycle, C. trachomatis uses a
type III secretion system (T3SS) to translocate several ef-
fector proteins across the host cell plasma membrane and
the inclusion membrane [4,5]. These T3S effectors areral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and exit of host cells [8], and in the subversion of various
host cell processes [9-16]. There are, however, chlamydial
effectors, such as CPAF/CT858 or CT441, which are not
T3S substrates [4].
Given their likely central role during infection, consi-
derable efforts have been placed at identifying chlamy-
dial effectors. This is not a trivial task because the amino
acid sequence of most effectors does not display signifi-
cant similarity to proteins of known function. Additio-
nally, T3S substrates, which should comprise the bulk of
Chlamydia effectors, contain no easily recognizable se-
cretion signal. Moreover, in spite of the recent deve-
lopment of systems for transformation of Chlamydia
[17,18], for a long time no methods have been available
for genetic manipulation of these bacteria. To overcome
these obstacles, chlamydial effectors have been searched:
i) by systematic phenotypic analyses of yeast Saccharomy-
ces cerevisiae expressing individual chlamydial proteins
[19]; ii) by using Salmonella [20], Shigella [15,21-23], or
Yersinia [13,14,24-27] as genetically tractable heterologous
host bacteria carrying well characterized T3SSs; or iii) by
complex computational predictions of T3S signals [28-30].
The subsequent use of specific antibodies enabled to de-
tect translocation into host cells of some of the C. tracho-
matis proteins singled out in these searches, such as in the
case of Tarp/CT456 [25], CT694 [14], CopN/CT089 [24],
Cap1/CT529 [31], CT620 [22], CT621 [22,32], CT711
[22], lipid-droplet associated (Lda) proteins Lda1/CT156,
Lda2/CT163, and Lda3/CT473 [33], Nue/CT737 [15], or
of a group of proteins containing a hydrophobic motif
thought to mediate their insertion into the inclusion
membrane (Inc proteins) [12,34]. Moreover, the direct use
of antibodies raised against particular C. trachomatis pro-
teins (CT311, CT622, CT795, GlgA/CT798, HtrA/CT823,
or Pgp3) revealed their presence in the host cell cytosol or
nucleus of infected cells [35-40]. Finally, the in vitro deu-
biquitinase activity of ChlaDUB1/CT868 and of Chla-
DUB2/CT867 [41], and the capacity of ChlaDUB1/CT868
to suppress the NF-κB pathway in transfected cells [42],
indicate that these two proteins should be effectors.
In this work, we have surveyed the genome of C.
trachomatis mostly for genes encoding uncharacterized
proteins that were not described before as T3S sub-
strates. We then used Yersinia enterocolitica as a
heterologous system to identify 10 novel likely T3S sub-
strates of C. trachomatis and real-time quantitative PCR
(RT-qPCR) to show that 9 of the genes encoding these
proteins are clearly expressed during the bacterial deve-
lopmental cycle. Furthermore, we showed that 7 of the
10 likely T3S substrates of C. trachomatis could be
translocated into host cells by Y. enterocolitica. There-
fore, we identified several novel putative effectors of
C. trachomatis.Methods
Cell culture, bacterial strains and growth conditions
HeLa 229 (ATCC) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen) supple-
mented with 10% (v/v) foetal bovine serum (FBS; Invitro-
gen) at 37°C in a humidified atmosphere of 5% (v/v) CO2.
C. trachomatis L2/434/Bu (from ATCC) was propagated
in HeLa 229 cells using standard techniques [43]. Escheri-
chia coli TOP10 (Invitrogen) was used for construction
and purification of the plasmids. Yersinia enterocolitica
ΔHOPEMT (MRS40 pIML421 [yopHΔ1-352, yopOΔ65-558,
yopP23, yopE21, yopM23, yopT135]), deficient for the Yersinia
T3S effectors YopH, O, P, E, M, and T, but T3S-proficient
[44] and T3S-deficient Y. enterocolitica ΔHOPEMT
ΔYscU (MRS40 pFA1001 [yopHΔ1-352, yopOΔ65-558, yopP23,
yopE21, yopM23, yopT135, yscUΔ1-354) [45] were used for
T3S assays. The yscU gene encodes an essential compo-
nent of the Y. enterocolitica T3S system, and the yscUΔ1-354
mutation is non-polar [46]. E. coli or Y. enterocolitica were
routinely grown in liquid or solid Luria-Bertani (LB) me-
dium (NZYtech) with the appropriate antibiotics and sup-
plements. Plasmids were introduced into E. coli or Y.
enterocolitica by electroporation.
DNA manipulations, plasmids, and primers
The plasmids used in this work and their main charac-
teristics are detailed in Additional file 1: Table S1. The
DNA primers used in their construction are shown in
Additional file 2: Table S2. Plasmids were constructed and
purified with proof-reading Phusion DNA polymerase
(Finnzymes), restriction enzymes (MBI Fermentas), T4
DNA Ligase (Invitrogen), DreamTaq DNA polymerase
(MBI Fermentas), DNA clean & concentrator™-5 Kit and
Zymoclean™ Gel DNA Recovery kit (Zymo Research), and
purified with GeneElute Plasmid Miniprep kit (Sigma), ac-
cording to the instructions of the manufacturers. In brief,
to analyze T3S signals we constructed plasmids harboring
hybrid genes encoding the first 10, 15, 20, or 40 amino
acids of each protein (C. trachomatis proteins, SycT and
YopE) and the mature form of TEM-1 β-lactamase (TEM-
1) [47]. These hybrids were made using as vector pLJM3,
a low-copy plasmid which enables expression of the
cloned genes driven by the promoter of the Y. enterocoli-
tica yopE gene [48], either by overlapping PCR or by using
a cloning strategy previously described for the construc-
tion of plasmids encoding Inc-TEM-1 hybrid proteins
[45]. To analyze secretion of full-length C. trachomatis
proteins, we constructed plasmids expressing the proteins
C-terminally tagged with a haemagglutinin (HA) epitope.
For this, the genes were amplified by PCR from chromo-
somal DNA of strain L2/434/Bu using a reverse primer
with a sequence complementary to the transcribed strand
of the DNA encoding the HA-epitope. PCR products
digested with the appropriate enzymes were ligated into
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all the inserts in the constructed plasmids was checked by
DNA sequencing.
Y. enterocolitica T3S assays
T3S assays were done as previously described [46]. We
used Y. enterocolitica ΔHOPEMT or ΔHOPEMT ΔYscU
strains carrying the plasmids described in Additional file 1:
Table S1. The proteins in bacterial pellets and culture
supernatants were analyzed by immunoblotting, and the
amounts of protein in bacterial pellets and/or culture
supernatants were estimated from images of immunoblots
with Image Lab (Bio-Rad). Where appropriate, we calcu-
lated the percentage of secretion as the ratio between the
amounts of secreted protein (in the culture supernatant
fraction) relative to the total amount of protein (in the
culture supernatant and in the bacterial pellet fractions).
The results from the quantifications are the average ±
standard error of the mean (SEM) from at least three inde-
pendent experiments. Detailed results for each protein
analyzed are in Additional file 3: Table S3.
Y. enterocolitica translocation assays
Analyses of protein translocation into host cells by
Y. enterocolitica were done essentially as previously des-
cribed [49,50]. In brief, Y. enterocolitica strains were
grown in brain heart infusion (BHI; Scharlau) medium
overnight at 26°C with continuous shaking (130 rpm).
Bacteria were then diluted to an optical density at 600 nm
of 0.2 in fresh BHI and cultured in the same conditions
for 2 h. Subsequently, the yop regulon was induced by
incubation for 30 min in a shaking water bath (130 rpm)
at 37°C. Bacteria were then washed with DMEM supple-
mented with 10% (v/v) FBS and added to HeLa 229 cells,
grown overnight in 24-well plates (1x105 cells/well), by
using a multiplicity of infection of 50. The infected cells
were incubated at 37°C in a humidified atmosphere of 5%
(v/v) CO2. After 3 h of incubation, extracellular bacteria
were killed by adding gentamicin (50 μg/ml), and the cells
were incubated in the same conditions for additional 2 h.
The infected cells were then harvested on ice, washed with
phosphate-buffered saline (PBS), ressuspended in PBS
containing 0.1% (v/v) Triton X-100 and a protease inhibi-
tor cocktail (Sigma), and incubated for 10 min on ice. The
samples were centrifuged (15,000 g for 15 min at 4°C) and
Triton-soluble and Triton-insoluble HeLa cell lysates were
loaded on sodium dodecyl sulfate-12% (v/v) polyacrila-
mide gels. After electrophoresis, the gels were processed
for immunoblotting using 0.2 μm pore-size nitrocellulose
membranes (BioRad).
Immunoblotting
The following antibodies were used for immunoblotting: rat
monoclonal anti-HA (clone 3F10; Roche; used at 1:1000),mouse monoclonal anti-TEM-1 (QED Bioscience; 1:500),
rabbit polyclonal anti-SycO (1:1000) [51], and mouse
monoclonal anti-tubulin (clone B-5-1-2; Sigma; 1:1000).
Immunoblot detection was done with horseradish peroxi-
dase-conjugated secondary antibodies (GE Healthcare and
Jackson ImmunoResearch), Western Lightning Plus-ECL
(Perkin Elmer), and a ChemiDoc XRS + system (BioRad) or
exposure to Amersham Hyperfilm ECL (GE Healthcare).
All quantitative analyses were done with immunoblot
images obtained using ChemiDoc XRS + (BioRad).
Real-time quantitative PCR
The expression of the newly identified candidate T3S sub-
strates during the developmental cycle of C. trachomatis
L2/434 was estimated by determining mRNA levels at dif-
ferent times post-infection by real-time quantitative PCR
(RT-qPCR). These experiments were done as previously
described [45]. Primers (available upon request) were de-
signed using Primer Express (Applied Biosystems). The
RT-qPCR assays were done using the ABI 7000 SDS, SYBR
green chemistry, and optical plates (Applied Biosystems),
as previously described [52]. At each time point, raw
RT-qPCR data for each gene were normalized against the
data obtained for the 16S rRNA transcript, as it was pre-
viously demonstrated that this is an adequate endogenous
control [52]. The final results were based on three inde-
pendent experiments.
Results
Selection of C. trachomatis proteins analyzed in this work
To search for previously unidentified T3S substrates of
C. trachomatis, we first surveyed the genome of strain
L2/434 for genes encoding mostly uncharacterized pro-
teins, or with a putative biochemical activity compatible
with the function of a T3S effector (e.g., proteases).
Among these genes, we selected those encoding proteins
not predicted to have a signal sequence characteristic of
the general secretory pathway (according to Psortb v3.0)
and that had not been previously analyzed experimentally
for the presence of a T3S signal. This singled out 32 pro-
teins (CT016, CT017, CT031, CT051, CT053, CT080,
CT105, CT142, CT143, CT144, CT153, CT161, CT172,
CT273, CT277, CT289, CT309, CT330, CT338, CT386,
CT425, CT568, CT583, CT590, CT631, CT635, CT656,
CT696, CT702, CT837, CT845, and CT849; we used the
nomenclature of the annotated C. trachomatis D/UW3
strain [53]; the names of the corresponding genes as an-
notated for strain L2/434 [54] can be found in Additional
file 3: Table S3). Furthermore, for comparison purposes,
we considered proteins that had been tested for the pre-
sence of a T3S signal using Shigella flexneri as a hetero-
logous bacteria: eight proteins whose first ~40 amino
acids of the corresponding C. pneumoniae homologs did
not drive secretion of an adenylate cyclase (Cya) reporter
Figure 1 The first 20 amino acids of known C. trachomatis T3S
substrates (IncA or IncC) are sufficient to efficiently drive T3S
of TEM-1 hybrid proteins by Y. enterocolitica. Y. enterocolitica
T3S-proficient (ΔHOPEMT) (A) and T3S-defective (ΔHOPEMT ΔYscU)
(B) were used to analyze secretion of hybrid proteins comprising the
first 10, 20, or 40 amino acids of C. trachomatis IncA or IncC, or the first
15 or 20 amino acids of Y. enterocolitica YopE or SycT, respectively,
fused to the mature form of TEM-1 β-lactamase (TEM-1). Immunoblots
show the result of T3S assays in which proteins in culture supernatants
(S, secreted proteins) and in bacterial pellets (P, nonsecreted proteins)
from ~5x107 bacteria were loaded per lane. The first 15 amino acids of
the Yersinia effector YopE correspond to an archetypal T3S signal
[57,58], and YopE15-TEM-1 was used as positive control; SycT and SycO
are strictly cytosolic Yersinia T3S chaperones [44,51]. SycT20-TEM-1
was a negative control for the T3S assays. Immunodetection of SycO
ensured that the presence of TEM-1 hybrid proteins in the culture
supernatants was not a result of bacterial lysis or contamination. The
percentage (%) of secretion of each TEM-1 hybrid was calculated by
densitometry, as the ratio between the amount of secreted and total
protein. The threshold to decide whether a protein was secreted was
set to 5% (dashed line), based on the % of secretion of SycT20-TEM-1.
Data are the mean ± SEM from at least 3 independent experiments.
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CT538, CT584, CT768, CT779, CT814), and three pro-
teins whose N-terminal region of the C. pneumoniae
homologs drove secretion of a Cya reporter protein by
S. flexneri (CT203, CT577, CT863) [21]. Please note that
at the time this work was initiated GrgA/CT504 was an
uncharacterized protein; however, it was recently described
as a transcriptional activator [55]. Finally, throughout this
study we used as positive controls a C. trachomatis bona-
fide T3S effector (CT694) [14] and a C. trachomatis likely
T3S substrate (CT082) that we had previously identified
[26], and which was recently independently confirmed
[27], and as negative control a predicted ribosomal protein
(RplJ/CT317).
In summary, in experiments that will be described below,
we analyzed T3S signals in 46 C. trachomatis proteins
(~5% of all proteins encoded by the L2/434 strain): 32
hypothetical proteins previously not analyzed experimen-
tally for T3S signals, 11 proteins whose C. pneumoniae
homologs were previously analyzed for T3S signals using
S. flexneri as heterologous system, and 3 controls. In the
selection of these proteins, we did not consider predictions
made by any of the published in silico methods that sug-
gest putative T3S substrates [28-30,56].
The first 20 amino acids of C. trachomatis T3S substrates
are sufficient to drive efficient secretion of TEM-1 hybrid
proteins by Y. enterocolitica
We previously used TEM-1 as a reporter protein to
analyze T3S signals in C. trachomatis Inc proteins, using
Y. enterocolitica as a heterologous system [45]. However,
before analyzing T3S signals in the proteins that we
selected to study in this work (see above), we sought to
ascertain the optimal amino acid length of the chlamydial
T3S signal that drives secretion of TEM-1 hybrid proteins
in Yersinia. For this, we analyzed secretion of hybrid pro-
teins comprising the first 10, 20 and 40 amino acids of
known C. trachomatis T3S substrates (IncA or IncC)
fused to TEM-1 (IncA10-TEM-1, IncA20-TEM-1, IncA40-
TEM-1, IncC10-TEM-1, IncC20-TEM-1, IncC40-TEM-1)
by T3S-proficient (ΔHOPEMT) or T3S-deficient (ΔHO-
PEMT ΔYscU) Y. enterocolitica (Figure 1). As negative
controls we analyzed secretion by Y. enterocolitica ΔHO-
PEMT of TEM-1 alone and of a hybrid protein com-
prising the first 20 amino acids of the Yersinia T3S
chaperone SycT to TEM-1 (SycT20-TEM-1), and as posi-
tive control we analyzed secretion by ΔHOPEMT of a
fusion of the first 15 amino acids of the Yersinia effector
YopE to TEM-1 (YopE15-TEM-1) (Figure 1), an archetypal
T3S signal [57,58]. Bacteria expressing these proteins were
incubated under T3S-inducing conditions, as described in
Methods. As expected, and in agreement to what we pre-
viously reported [45], mature TEM-1 alone was not se-
creted and the SycT20-TEM-1 fusion showed a percentage
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TEM-1 hybrid was secreted or not, we set the threshold of
percentage of secretion to 5 (Figure 1A). The six Inc-TEM-
1 hybrid proteins were type III secreted (Figure 1A and B).
However, IncA10-TEM-1 and IncC10-TEM-1 were secreted
less efficiently than YopE15-TEM-1, while IncA20-TEM-1,
IncA40-TEM-1, IncC20-TEM-1 and IncC40-TEM-1 were se-
creted at levels comparable to YopE15-TEM-1 (Figure 1A).
Overall, these experiments indicated that the first 20 amino
acids of C. trachomatis T3S substrates are sufficient to drive
secretion of TEM-1 hybrid proteins by Y. enterocolitica
ΔHOPEMT as efficiently as the first 15 amino acids of the
Yersinia effector YopE.
Identification of T3S signals in C. trachomatis proteins
To identify T3S signals in the selected 46 C. trachomatis
proteins, we analyzed secretion of fusions to TEM-1 of the
first 20 amino acids of each of these proteins by T3S-
proficient Y. enterocolitica ΔHOPEMT. These experiments
revealed 24 C. trachomatis proteins whose first 20 amino
acids drove secretion of TEM-1 hybrid proteins by Y.
enterocolitica (Figure 2A). Owing to lack of expression, or
very low expression levels, it was not possible to conclude
if the TEM-1 hybrids comprising the N-terminal region of
CT590, CT845 and CT863 were secreted (Figure 2A). By
individually introducing the plasmids encoding the TEM-1
hybrid proteins that were secreted into T3S-deficient Y.
enterocolitica ΔHOPEMT ΔYscU and performing T3S
assays, we confirmed that secretion of the proteins was
dependent on a functional T3SS (Figure 2B). The percen-
tage of secretion of the different hybrid proteins that were
secreted varied considerable, between 56% (SEM, 4) for
CT69420-TEM-1 to 5% (SEM, 2) for CT14320-TEM-1
(Figure 2B). Overall, this confirmed a T3S signal in CT203,
which has been previously shown to be a T3S substrate
[21], and revealed T3S signals in 23 previously T3S sub-
strates of C. trachomatis.
Analysis of the secretion of the newly identified
candidate T3S substrates of C. trachomatis as full-length
proteins
We next analyzed if the 23 C. trachomatis proteins car-
rying newly identified T3S signals, and also CT203 and
the controls (CT082, CT694 and RplJ), were secreted as
full-length proteins by Y. enterocolitica ΔHOPEMT. The
rationale for these experiments was that some proteins
cannot be type III secreted even with a T3S signal grafted
at their N-termini [59-62], possibly because the secretion
channel is too narrow (inner diameter of 2–3 nm [63]) to
accommodate tightly folded proteins. For example, while
we showed that YopE15-TEM-1 is efficiently type III se-
creted, hybrid proteins containing the first 15 or 16 amino
acids of YopE fused to mouse dihydrofolate reductase
(DHFR) are not type III secreted by Y. enterocolitica[59,60]. This indicates that most T3S substrates must have
particular folding properties that are compatible with
them being type III secreted proteins. Based on this, we
predicted that if the full-length version of chlamydial pro-
teins were type III secreted by Yersinia this would be an
additional indication that they can be T3S substrates.
However, lack of secretion of the full-length proteins
would not preclude that they could be T3S substrates, as
they may require Chlamydia-specific chaperones, not
present in Yersinia [64].
To analyze secretion of full-length C. trachomatis pro-
teins by Y. enterocolitica we used plasmids expressing the
chlamydial proteins with an HA tag at their C-termini.
The plasmids were introduced into Y. enterocolitica ΔHO-
PEMT and T3S assays were performed. In these experi-
ments, the percentage of secretion of the positive controls
(CT694-HA and CT082-HA) was between 20-30% and
the percentage of secretion of the negative control (RplJ-
HA) was 0.13% (SEM, 0.05). Based on these results, in
experiments involving full-length proteins of newly identi-
fied chlamydial T3S substrates we set a conservative
threshold of 2% to decide whether a protein was secreted
or not. This defined a group of 11 proteins that in their
full-length version were secreted by Y. enterocolitica ΔHO-
PEMT: CT053-HA, CT105-HA, CT142-HA, CT143-HA,
CT144-HA, CT161-HA, CT338-HA, CT429-HA, CT583-
HA, CT656-HA, and CT849-HA (Figure 3A and B). To
test if secretion of these proteins was dependent on a func-
tional T3SS, the plasmids carrying their encoding genes, as
well as plasmids encoding positive controls CT694-HA
or CT082-HA, were individually introduced into T3S-
deficient Y. enterocolitica ΔHOPEMT ΔYscU. With the
exception of CT583-HA, which for unknown reasons was
very poorly expressed by Y. enterocolitica ΔHOPEMT
ΔYscU, these assays indicated that the other 10 proteins
analyzed were type III secreted (Figure 3C).
Secretion of full-length CT153-HA, CT172-HA,
CT203-HA, CT386-HA or CT425-HA by Y. enterocolitica
could occasionally be seen by immunoblotting (Figure 3A);
however, this was not always reproducible and individual
average percentage of secretion of these proteins was in all
cases below 2% (Figure 3B). We did not detect signifi-
cant amounts of CT273-HA, CT289-HA, CT309-HA,
or CT631-HA in culture supernatants (Figure 3A and
Additional file 3: Table S3), but as their levels of expres-
sion were either extremely low (CT273-HA, CT289-HA,
and CT309-HA) or undetectable (CT631-HA) it was not
possible to draw conclusions about secretion of these pro-
teins. Furthermore, CT016-HA, and possibly CT696-HA
(barely visible in Figure 3A), were immunodetected in the
culture supernatant fraction in a form that migrated on
SDS-PAGE at a molecular weight much lower than the
one predicted from their amino acid sequence (27 kDa
and 46 kDa, respectively), while in the bacterial pellet
Figure 2 (See legend on next page.)
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Figure 2 Identification of T3S signals in C. trachomatis proteins using Y. enterocolitica as a heterologous system. Y. enterocolitica T3S-
proficient (ΔHOPEMT) (A) and T3S-defective (ΔHOPEMT ΔYscU) (B) were used to analyze secretion of hybrid proteins comprising the first 20 amino
acids of selected C. trachomatis proteins or the first 20 amino acids of Y. enterocolitica SycT fused to the mature form of TEM-1 β-lactamase (TEM-1).
Immunoblots show the result of T3S assays in which proteins in culture supernatants (S, secreted proteins) and in bacterial pellets (P, non-secreted
proteins) from ~2.5x108 and ~5x107 bacteria, respectively, were loaded per lane. TEM-1 hybrids of the known C. trachomatis T3S substrates CT082
[26,27] and CT694 [14] were used as positive controls. SycT and SycO are strictly cytosolic Yersinia T3S chaperones [44,51]. SycT20-TEM-1 was a negative
control for the T3S assays. Immunodetection of SycO ensured that the presence of TEM-1 hybrid proteins in the culture supernatants was not a result
of bacterial lysis or contamination. The percentage (%) of secretion of each TEM-1 hybrid was calculated by densitometry, as the ratio between the
amount of secreted and total protein. The threshold to decide whether a protein was secreted was set to 5% (dashed line), based on the% of secretion
of SycT20-TEM-1. Data are the mean ± SEM from at least 3 independent experiments.
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roughly to their predicted molecular weight (Figure 3A).
This suggests that the proteins could be cleaved during
secretion, unstable in the culture supernatant, or their en-
coding genes possess internal Shine-Dalgarno sequences.
Regardless of the exact reason, we could not confidently
analyze whether CT016-HA and CT696-HA were se-
creted or not.
Overall, the full set of T3S assays revealed 10 proteins
(CT053, CT105, CT142, CT143, CT144, CT161, CT338,
CT429, CT656, and CT849) as newly identified likely
T3S substrates of C. trachomatis, and therefore as pos-
sible effectors.
CT053, CT105, CT142, CT143, CT161, CT338, and CT429
can be translocated into host cells by Y. enterocolitica
We next analyzed if the newly identified likely T3S
substrates of C. trachomatis had the capacity of being
translocated into host cells, by using Y. enterocolitica as a
heterologous system. For this, Y. enterocolitica ΔHOPEMT
harboring plasmids encoding C-terminal HA-tagged newly
identified likely T3S substrates of C. trachomatis (CT053-
HA, CT105-HA, CT142-HA, CT143-HA, CT144-HA,
CT161-HA, CT338-HA, CT429-HA, CT656-HA, or
CT849-HA), a positive control (CT694-HA) or a negative
control (RplJ-HA), were used to infect human epithelial
HeLa cells. We then used Triton X-100 fractionation of
the infected cells followed by immunoblotting analysis of
Triton-soluble and insoluble HeLa cell lysates to monitor
protein translocation into host cells. As expected, we
found CT694-HA in the Triton-soluble fraction, which
showed that this protein was delivered into the cytoplasm
of HeLa cells, and only detected RplJ-HA in the Triton-
insoluble fraction (Figure 4), which confirmed that this
protein remained within the bacteria (and that the frac-
tionation procedure did not lyse the bacteria). Among the
10 likely T3S substrates of C. trachomatis under analysis,
we could not detect CT656-HA or CT849-HA in both the
Triton-soluble and Triton-insoluble fractions. It is possible
that in the experimental conditions used in this study
CT656-HA or CT849-HA are translocated in minute and
undetectable amounts and/or that they are degraded either
after translocation or within the bacteria. Regardless of theexact scenario, these results did not enable us to conclude
about the capacity of CT656-HA and CT849-HA of being
translocated into host cells. However, we could con-
sistently detect CT053-HA, CT105-HA, CT142-HA,
CT143-HA, CT161-HA, CT338-HA and CT429-HA in
the Triton-soluble fraction (Figure 4), indicating that these
proteins were injected into the cytoplasm of HeLa cells by
Y. enterocolitica. We could also occasionally detect small
amounts of CT144-HA in the Triton-soluble fraction
(barely visible in Figure 4).
In summary, these experiments showed that CT053-HA,
CT105-HA, CT142-HA, CT143-HA, CT161-HA, CT338-
HA and CT429-HA have the capacity of being tran-
slocated into infected host cells further suggesting that the
endogenous C. trachomatis proteins could be effectors.
The results do not preclude that CT144, CT656 or CT849
could be effectors, but the evidence is not as strong as for
the other 7 proteins.
Expression of genes encoding newly identified likely T3S
substrates during development of C. trachomatis
To test if the newly identified likely T3S substrates, and
possible effectors, of C. trachomatis (CT053, CT105,
CT142, CT143, CT144, CT161, CT338, CT429, CT656,
and CT849) were expressed during infection, and to gain
insights of when they could be acting during the develop-
mental cycle, we analyzed by RT-qPCR the mRNA levels
of their encoding genes during the developmental cycle of
strain L2/434, at 2, 6, 12, 20, 30 and 42 h post-infection.
While ct053, ct105, ct142, ct143, ct144, ct338, ct429, ct656,
and ct849 displayed significant mRNA levels in more than
one of the time-points analyzed, ct161 showed only ves-
tigial levels of expression throughout the cycle (Figure 5).
The mRNA levels of ct105 and ct338 were > 5-fold higher
at 2–6 h post-infection than in any other of the time-
points analyzed (Figure 5), suggesting that the encoded
proteins should function at early-cycle. The mRNA levels
of ct053 and ct429 were higher between 6 and 20 h post-
infection (Figure 5), suggesting that the encoded proteins
might act from early to mid cycle. The mRNA levels of
ct142, ct143, ct144 and ct849 were higher at the later time
points analyzed (30–42 h post-infection). However, while
ct142, ct143, and ct144 were expressed at similar levels at
Figure 3 (See legend on next page.)
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Figure 3 Analysis of the T3S of C. trachomatis full-length proteins by Y. enterocolitica. Y. enterocolitica T3S-proficient (ΔHOPEMT) (A) and
T3S-defective (ΔHOPEMT ΔYscU) (B) were used to analyze secretion of full-length C. trachomatis proteins with a C-terminal HA epitope tag.
Immunoblots show the result of T3S assays in which proteins in culture supernatants (S, secreted proteins) and in bacterial pellets (P, non-secreted
proteins) from ~5 x 108 and ~5 x 107 bacteria, respectively, were loaded per lane. The known C. trachomatis T3S substrates CT082 [26,27] and CT694
[14] were used as positive controls, and the C. trachomatis ribosomal protein RplJ was used as a negative control. SycO is a strictly cytosolic Yersinia
T3S chaperone [44,51] and its immunodetection ensured that the presence of HA-tagged proteins in the culture supernatants was not a result of
bacterial lysis or contamination. (C) The percentage (%) of secretion of each protein by Y. enterocolitica ΔHOPEMT was calculated by densitometry, as
the ratio between the amount of secreted and total protein. The threshold to decide whether a protein was secreted was set to 2% (dashed line),
based on the % of secretion of RplJ-HA. Data are the mean ± SEM from at least 3 independent experiments.
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expression at 30 h post-infection (Figure 5). Therefore,
CT142, CT143, CT144 could function either at late or
early cycle, and CT849 might probably acts at late cycle.
Finally, the mRNA levels of ct656 were constant at all
time-points analyzed (Figure 5), suggesting that CT656
could function throughout the cycle. Regarding ct161,
when comparing the higher mRNA levels detected for
each of the genes analyzed, those of ct161 were > 6-fold
lower than those of any of the other genes tested (Figure 5).
Therefore, in the experimental conditions used, CT161
may not be expressed by strain L2/434. In summary, the
RT-qPCR experiments supported that CT053, CT105,
CT142, CT143, CT338, and CT429, and also CT144,
CT656, or CT849, could be C. trachomatis T3S effectors,
possibly acting at different times of the developmental
cycle.
Discussion
Earlier studies using heterologous systems have led to the
identification of several bona-fide or putative C. trachoma-
tis T3S effectors [13-15,21,22,24,25,26,27]. While these
and other analyses covered a significant portion of all
C. trachomatis proteins, we hypothesized that there could
be previously unidentified T3S substrates. By combining
basic bioinformatics searches, exhaustive T3S assays,
translocation assays, and analyses of chlamydial gene ex-
pression in infected cells, we revealed 10 C. trachomatis
proteins (CT053, CT105, CT142, CT143, CT144, CT161,
CT338, CT429, CT656, and CT849) as likely T3S sub-
strates and possible effectors. In particular, CT053,
CT105, CT142, CT143, CT338, and CT429 were type III
secreted by Y. enterocolitica, could be translocated into
host cells, and their encoding genes were clearly expressed
in C. trachomatis strain L2/434. Therefore, these 6 pro-
teins have a high likelihood of being effectors. However,
additional future studies are required to show that all of
these 10 proteins are indeed translocated by C. trachoma-
tis into host cells and to show that they are bona-fide
effectors, i.e., that they interfere with host cell processes.
Among the likely T3S effectors of C. trachomatis that
we identified, CT105 and CT142 have been previously
singled out as possible modulators of host cell functions,
based on the phenotypic consequences of their ectopicexpression in yeast S. cerevisiae [19]. In addition, the
genes encoding CT142, CT143, and CT144 have been
shown to be markedly transcriptionally regulated by a
protein (Pgp4) encoded by the Chlamydia virulence
plasmid [65]. This plasmid is present in almost all C.
trachomatis clinical isolates [66], and studies in animal
models of infection showed that it is a virulence factor
in vivo [67,68]. Additional studies are needed to under-
stand if the putative effector function of CT142, CT143,
and CT144 can partially explain the virulence role of the
chlamydial plasmid. Furthermore, the predicted amino
acid sequence of CT849 reveals a domain of unknown
function (DUF720) that can only be found in Chlamydia
proteins. In C. trachomatis, besides CT849, a DUF720
domain is found in CT847, a T3S effector that interacts
with human Grap2 cyclin D-interacting protein (GCIP)
[13], and in CT848, which has been indicated as a T3S
substrate using S. flexneri as a heterologous system [21].
Therefore, this further supports a possible role of CT849
as an effector. In contrast with CT105, CT142, CT143,
CT144 or CT849, no significant information is available
or could be retrieved about CT053, CT338, CT429, or
CT656.
CT161 is a possible T3S substrate and effector, but we
could not detect significant levels of ct161 mRNA during
the developmental cycle of strain L2/434. The ct161 gene
is localized within the “plasticity zone”, a chromosomal
region of rare high genetic diversity among C. trachomatis
strains. In fact, although C. trachomatis includes strains
showing remarkably different tropisms (strains that can
spread into lymph nodes and cause lymphogranuloma
venereum [LGV], such as L2/434, and strains causing in-
fections usually restricted to the mucosa of the conjunc-
tiva and genitals), their genomes are all highly similar [69].
Preliminary data indicate that, contrarily to what is seen
in LGV strains, the ct161 seems to be more expressed in
some ocular and urogenital isolates (data not shown). We
are currently investigating the possibility that ct161 is a
pseudogene in LGV strains, perhaps inactivated by a
mutation in its promoter region. Interestingly, CT161 has
been shown by yeast two-hybrid to bind CT274 (a pos-
sible chlamydial T3S chaperone) [70]. Another feature of
this protein is that part of its amino acid sequence (resi-
dues 40–224, out of 246) shows 28% of identity to a region
Figure 4 Translocation of C. trachomatis proteins into the cytoplasm of HeLa cells by Y. enterocolitica. HeLa cells were left uninfected (UI)
or infected with Y. enterocolitica ΔHOPEMT strains expressing the indicated HA-tagged proteins. After 3 h of infection, extracellular bacteria were killed
by the addition of gentamicin and the infected cells were incubated for additional 2 h. The infected cells were then fractionated into Triton-soluble
and Triton-insoluble cell lysates that were subsequently analyzed by immunoblotting using anti-HA, anti-SycO and anti-tubulin antibodies, as indicated.
Presence of HA-tagged proteins in the Triton-soluble cell lysates is indicative of translocation into the cytoplasm of HeLa cells. SycO is a strictly cytosolic
Yersinia T3S chaperone [44,51] and its immunodetection ensured that the presence of HA-tagged proteins in the Triton-soluble cell lysates was not a
result of bacterial lysis during the fractionation. Additionally, the incapacity to detect HA-tagged RplJ (a C. trachomatis ribosomal protein) in the
Triton-soluble cell lysates further indicated that this fraction did not contain bacteria or non-translocated bacterial proteins. Tubulin served as a loading
control of the Triton-soluble cell lysates. The images shown are representative of three independent experiments.
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C. trachomatis translocated protein [33].
Among the proteins for which we found a secretion sig-
nal but could not demonstrate their T3S as full-length
proteins, we highlight CT153 and GrgA/CT504. Regar-
ding CT153, this protein possesses a membrane attack
complex/perforin (MACPF) domain [71], and there is pre-
vious evidence that it may be translocated by C. tracho-
matis [72], which is consistent with our data. The ct504
gene has been recently shown to encode a transcriptional
activator, GrgA [55]. Therefore, T3S of CT50420-TEM-1
could be false a positive. However, if GrgA is a T3S sub-
strate, as our data suggests, it could have a function within
the host cell or, more likely and similarly to what has been
described in the T3SSs of Yersinia [73] or Shigella [74,75],
it could be discarded by secretion once its intra-bacterial
regulatory activity needs to be shut down.
We found T3S signals in 56% proteins analyzed (26 out
of 46, including controls). This high percentage of proteins
showing a T3S signal suggests that some should be falsepositives. It is conceivable that within a single bacterium
non-secreted proteins possess T3S signals but are not
targeted to the T3SS machinery because they also carry
signals (e.g. DNA-, membrane-, or protein-binding) that
preferentially direct them to other location within the bac-
terial cell. To help differentiating between true or false
positives among chlamydial proteins carrying a T3S signal
we analyzed their secretion as full-length proteins. This is
because, as explained above in the Results section, not all
proteins have folding characteristics compatible with T3S
[59-62]. However, we cannot exclude that some of the
C. trachomatis full-length proteins that were not type III
secreted by Yersinia have a T3S chaperone that maintains
them in a secretion-competent state [64] and enables their
secretion during infection by C. trachomatis. Intriguingly,
CT082 or CT694 have dedicated T3S chaperones, CT584
and Slc1, respectively [26], and, in agreement with what
we previously observed [26], they were both secreted as
full-length proteins in the absence of the chaperones.
Considering that T3S chaperones have various functions
Figure 5 mRNA levels of newly identified putative effectors
during the developmental cycle of C. trachomatis. The mRNA
levels of ct053, ct105, ct142, ct143, ct144, ct161, ct338, ct429, ct656,
and ct849 were analyzed by RT-qPCR during the developmental
cycle of C. trachomatis strain L2/434, at the indicated time-points.
The expression values (mean ± SEM) resulted from raw RT-qPCR data
(105) of each gene normalized to that of the 16 s rRNA gene and
are from three independent experiments.
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different from maintaining their substrates in a secretion-
competent state.
Eleven of the Chlamydia proteins that we analyzed have
been previously studied for T3S using S. flexneri has a
heterologous system [21]. In the majority of the cases the
outcome of the experiments was identical; however, diffe-
rently from what was shown in Shigella, we detected a
T3S signal in the N-terminal of CT429 (which was also se-
creted as a full-length protein, and could be translocated
into HeLa cells), GrgA/CT504, and CT779 and we did not
detect a T3S signal in CT577. Evidence for a T3S signal inonly one of the heterologous systems may suggest a false
positive. However, there is a myriad of possible expla-
nations for these discrepancies, when considering that dif-
ferent heterologous systems (Shigella and Yersinia) and
reporter proteins (Cya and TEM-1) were used, and that
the N-terminal regions in the hybrid proteins consisted in
different lengths of amino acids and were in some cases
from different Chlamydia species.
We compared the data from our T3S assays (including
the controls, CT082, CT694, and RplJ) with predictions
of T3S substrates by in silico methods (Effective T3S
[28], SIEVE [29], Modlab [30], and T3_MM [56]) using
resources available in the Web (Effective T3S, Modlab
and T3_MM) and Table three in reference [29] (SIEVE),
as detailed in Additional file 3: Table S3. When consi-
dering the analysis of T3S signals in TEM-1 hybrids, the
vast majority of proteins (60%; 12 out of 20) in which we
did not find a T3S signal were also predicted not to be
secreted by each of the in silico methods. In contrast,
the vast majority of proteins (58%; 15 out of 26) in
which we detected a T3S signal were also predicted to
be secreted by at least one of the in silico methods. The
correlation between our experimental data and the in
silico predictions was more striking when considering
the T3S of full-length proteins. Among the 16 full-length
proteins for which we could not find definitive evidence
of T3S, 10 (i.e., 62.5%) were also predicted not to be se-
creted by each of the in silico methods, but among the
11 proteins that we showed or confirmed to be T3S sub-
strates, 10 (i.e., 83%) were also predicted to be secreted
by at least one of the in silico methods. Overall, this in-
dicates some correlation between our experimental data
and the in silico methods that predict T3S substrates.
However, for many proteins, each of these in silico
methods generates different predictions (see Additional
file 3: Table S3). It is possible that the quantitative data
on T3S such as the one we generated in this and in a
previous study [45], can be used to normalize and im-
prove the predictive value of such methods.
Conclusions
We found 10 C. trachomatis proteins (CT053, CT105,
CT142, CT143, CT144, CT161, CT338, CT429, CT656,
and CT849) with a high likelihood of being T3S sub-
strates, and therefore possible effectors delivered by the
bacteria into host cells. For 6 of these proteins (CT053,
CT105, CT142, CT143, CT338, and CT429), the hypoth-
esis that they could be effectors was supported by their
capacity of being translocated into host cells and by the
expression of their encoding genes by C. trachomatis. The
identification of all C. trachomatis effectors is a crucial
step towards a comprehensive understanding of the me-
chanisms by which this pathogen subverts host cells. The
recently developed methods for genetic manipulation of
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pically express candidate effectors in C. trachomatis
[17,78], which would facilitate the analysis of their
translocation into host cells. Our work highlights C. tra-
chomatis proteins that should be prioritized in such
studies, thus aiding the future identification of chlamyd-
ial effectors. Furthermore, the quantitative analysis of
T3S of TEM-1 hybrid proteins that we carried out could
help to further develop the in silico methods for identifi-
cation of T3S substrates [28-30,56].
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